Contact | Print version | PDF version | Send article | RSS-Feed

Affitech signs license agreement for single-chain antibody technology with Micromet

30 Mar 2007 - Affitech AS announced that it has signed an agreement with Micromet AG for a non-exclusive worldwide sub-licensable research license to the joint patent estate of Micromet and Enzon Pharmaceuticals, Inc. in the field of single-chain antibodies (SCA).
 
Under the terms of the agreement, Affitech will have rights to conduct research involving SCA technology and will have sublicense rights to third parties for the purpose of conducting research, develop or use an SCA product generated by Affitech. No other terms of the agreement were announced.